[Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab]

Suppl Tumori. 2004 Jul-Aug;3(4):S65-6.
[Article in Italian]
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy*
  • Clinical Trials, Phase III as Topic / methods*
  • Combined Modality Therapy
  • Endpoint Determination*
  • Female
  • Humans
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Taxoids / therapeutic use*
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • Trastuzumab